Though the information nonetheless must be scrutinized, Quebec firm Medicago says its newest trial suggests the COVID-19 vaccine it is produced with GlaxoSmithKline is exhibiting promise.
Their section 3 scientific trial discovered the two-dose vaccine to be 71 per cent efficient in opposition to most variants of COVID-19.
Nonetheless, Omicron was not included because the variant wasn’t identified about when the trial was performed.
Jamie Mauracher explains the place the Canadian-made shot is now within the approval course of and why it may assist struggle the pandemic past Canada.
For more information, please go to
Subscribe to International Information Channel HERE:
Like International Information on Fb HERE:
Comply with International Information on Twitter HERE:
Comply with International Information on Instagram HERE:
#GlobalNews #Medicago #COVID-19Vaccine